• Molecular NameNeostigmine
  • SynonymNA
  • Weight223.296
  • Drugbank_IDDB01400
  • ACS_NO59-99-4
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)-2.27
  • pka12
  • LogD (pH=7, predicted)-2.27
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)0.14
  • LogSw (predicted, AB/LogsW2.0)319.22
  • Sw (mg/ml) (predicted, ACD/Labs)308.09
  • No.of HBond Donors0
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds3
  • TPSA29.54
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA parasympathomimetic, specifically, a reversible cholinesterase inhibitor.
  • Absorption_value2.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability2.0
  • Protein binding20.0
  • Volume of distribution (VD)1.4 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmSlow hydrolysis by acetylcholinesterase and also by plasma esterases
  • Half life1.3 h
  • ExcretionUnchanged drug (up to 70%) and alcoholic metabolite (30%) are excreted in the urine
  • Urinary Excretion67
  • Clerance16.7 ml/min/kg
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A